NCT07346976

Brief Summary

The objective of this study is to ascertain the diagnostic threshold of end-tidal carbon monoxide (ETCOc, adjusted for ambient CO levels) within the first three days postpartum, stratified by neonatal age at birth. Additionally, the study aims to evaluate the concordance of the risk range of ETCOc, as measured by non-dispersive infrared spectroscopy, with existing literature, and to assess the reliability of this technology in the management of neonatal hyperbilirubinemia.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
14mo left

Started Dec 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress27%
Dec 2025Jul 2027

First Submitted

Initial submission to the registry

December 3, 2025

Completed
2 days until next milestone

Study Start

First participant enrolled

December 5, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 16, 2026

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2026

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2027

Last Updated

January 16, 2026

Status Verified

June 1, 2025

Enrollment Period

7 months

First QC Date

December 3, 2025

Last Update Submit

January 8, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • The ETCOc values of newborns were measured, and the optimal ETCOc threshold values between different time points of the TSB group were obtained.

    Establish an ETCOc diagnostic threshold for assessing the risk of hyperbilirubinemia in the early postnatal period based on the infant's age at birth. Determine the reliability and repeatability of ETCOc detection using non-dispersive infrared spectroscopy technology.Compare the concentrations of ETCOc between different groups and employ the ROC curve method to ascertain the optimal cut-off values of ETCOc at various time points across the TSB groups.

    The non-dispersive infrared spectroscopy technique was used to detect ETCOc in newborns at 12 hours, 24 hours, 48 hours and 72 hours after birth (the ETCOc detection should be completed within 4 hours at each time point)

  • The ETCOc values of newborns

    The ETCOc values of newborns were measured, and the optimal ETCOc threshold values between different time points of the TSB group were obtained.

    12 hours, 24 hours, 48 hours and 72 hours after the birth of the newborn

Study Arms (1)

term neonates

EXPERIMENTAL

The non-dispersive infrared spectroscopy technique was employed to measure the end-tidal carbon monoxide (ETCOc) levels in newborns at intervals of 12, 24, 48, and 72 hours post-birth.

Device: Erythrocyte Life Span Tester

Interventions

The non-dispersive infrared spectroscopy technique was employed to measure the end-tidal carbon monoxide (ETCOc) levels in newborns at intervals of 12, 24, 48, and 72 hours post-birth.

term neonates

Eligibility Criteria

Age0 Days - 28 Days
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Newborns with gestational age of ≥ 37 weeks and birth weight of ≥ 2.5 kg;
  • Newborns delivered by either vaginal delivery or cesarean section and with hospital stay of ≥ 3 days.

You may not qualify if:

  • History of second-hand smoke exposure within 24 hours
  • Parents smoke or are exposed to second-hand smoke.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

4th Affiliated Hospital, School of Medicine, Zhejiang University

Yiwu, Zhejiang, 322000, China

RECRUITING

MeSH Terms

Conditions

Hyperbilirubinemia, Neonatal

Condition Hierarchy (Ancestors)

Infant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHyperbilirubinemiaPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 3, 2025

First Posted

January 16, 2026

Study Start

December 5, 2025

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

July 1, 2027

Last Updated

January 16, 2026

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations